Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
KATALYST-AV
A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants With Moderate Calcific Aortic Valve STenosis
1 other identifier
interventional
1,276
2 countries
70
Brief Summary
The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Jun 2025
Longer than P75 for phase_2
70 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 13, 2025
CompletedFirst Posted
Study publicly available on registry
June 3, 2025
CompletedStudy Start
First participant enrolled
June 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2030
May 6, 2026
May 1, 2026
3.2 years
May 13, 2025
May 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
(Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24
Week 24
(Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48
Week 48
(Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48
Week 48
Secondary Outcomes (8)
(Part A) Correlation in the change in AVC as assessed by non-contrast CT and change in VO2 at Week 48
Week 48
(Part A) Change in VO2 from baseline to Week 48
Week 48
Change in left ventricular diastolic function as assessed by E/e' from baseline to Week 48
Week 48
(Part A) Change in Left Ventricular Mass Index (LVMI) from baseline to Week 48
Week 48
(Part A) Change in Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) from baseline to Week 48
Week 48
- +3 more secondary outcomes
Study Arms (2)
Ataciguat
EXPERIMENTALPlacebo
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Adult male or female at least 50 years of age
- Has moderate CAVS as defined by:
- An AVA of ≥1.0 cm2 to ≤1.50 cm2
- An AVC score between \>300 to 1200 Agatston units (AU) for women and between \>300 to 2000 AU for men
- Has a left ventricular ejection fraction (EF) of ≥45% at the time of Screening as determined by the echocardiography Imaging Core Laboratory
- For participants in CPET sub-study in Part A and all participants in Part B: If on beta blockade, the dose must be stable for at least 90 days prior to the Screening Visit with no anticipated changes during the study
You may not qualify if:
- For participants in the CPET sub-study in Part A and all participants in Part B: Has any medical or physical condition that, in the Investigator's opinion, could lead to an inability to complete Protocol-required CPET procedures (eg, pulmonary disease, joint, leg, hip, back conditions that limit physical activity, or other absolute contraindications for CPET)
- Anticipated or planned prior aortic valve replacement, repair, surgery, or intervention in the next 6 months
- Has moderate, moderate-to-severe, or severe (Grade 2 or higher) mitral stenosis, mitral regurgitation, and/or aortic regurgitation
- Has suspected or known congenital aortic valve disease including bicuspid aortic valve
- New York Heart Association (NYHA) Class IV heart failure symptoms and/or requires continuous inotropes
- Has history of hypertrophic, genetic/familial cardiomyopathy or cardiomyopathy related to amyloid or sarcoid
- Has untreated obstructive coronary artery disease or anticipating coronary stenting surgery
- Abnormal electrocardiogram (ECG) results or long-standing persistent or permanent atrial fibrillation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kardigan, Inc.lead
Study Sites (70)
University of Alabama at Birmingham (UAB) - Medical Center
Birmingham, Alabama, 35233, United States
Heart Center Research LLC
Huntsville, Alabama, 35801, United States
Onyx Clinical Research - Peoria
Peoria, Arizona, 85381, United States
Mayo Clinic - Phoenix
Phoenix, Arizona, 85259, United States
National Heart Institute
Beverly Hills, California, 90211, United States
UCLA Ronald Reagan Medical Center
Los Angeles, California, 90095, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
Profound Research LLC at Southern California Heart Specialists
Pasadena, California, 91105, United States
University of California, San Francisco (UCSF) - Medical Center
San Francisco, California, 94143, United States
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Torrance, California, 90502, United States
HCA Florida - JFK Hospital
Atlantis, Florida, 33462, United States
New Generation of Medical Research
Hialeah, Florida, 33016, United States
Memorial Healthcare System
Hollywood, Florida, 33021, United States
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216, United States
University of Miami
Miami, Florida, 33136, United States
New Generation of Medical Research - Naples
Naples, Florida, 34116, United States
Flourish Research - St. Augustine
Saint Augustine, Florida, 32086, United States
Sarasota Memorial Hospital
Sarasota, Florida, 34239, United States
University of South Florida
Tampa, Florida, 33606, United States
Wellstar Kennestone Hospital
Marietta, Georgia, 30060, United States
Northwestern University The Feinberg School of Medicine
Chicago, Illinois, 60611, United States
Ascension Heart and Vascular/Alexian Brothers Heart & Vascular Institute
Elk Grove Village, Illinois, 60007, United States
NorthShore University Health System
Glenview, Illinois, 60026, United States
Riverside Medical Center - Illinois
Kankakee, Illinois, 60901, United States
Midwest Cardiovascular Institute
Naperville, Illinois, 60540, United States
Methodist Medical Center of Illinois
Peoria, Illinois, 61636, United States
Midwest Cardiovascular Research and Education Foundation
Elkhart, Indiana, 46514, United States
University of Louisville Health
Louisville, Kentucky, 40202, United States
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Corewell Health
Royal Oak, Michigan, 48073, United States
Henry Ford Hospital
West Bloomfield, Michigan, 48322, United States
M Health Fairview St. John's Hospital
Maplewood, Minnesota, 55109, United States
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
Washington University
St Louis, Missouri, 63110, United States
Deborah Heart and Lung Center
Browns Mills, New Jersey, 08015, United States
Virtua Our Lady of Lourdes Hospital
Camden, New Jersey, 08103, United States
Atlantic Health System - Morristown Medical Center
Morristown, New Jersey, 85831, United States
Inspira Medical Centers
Mullica Hill, New Jersey, 08062, United States
Inspira Medical Center of Vineland
Vineland, New Jersey, 08302, United States
Albany Medical Center
Albany, New York, 12208, United States
University of Buffalo
Buffalo, New York, 14203, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
Duke University School of Medicine
Durham, North Carolina, 27710, United States
Moses H. Cone Memorial Hospital Operating Corporation d/b/a Cone Health
Greensboro, North Carolina, 27401, United States
Sanford Fargo
Fargo, North Dakota, 58122, United States
The Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio, 45219, United States
Bethesda North Hospital, TriHealth, Inc
Cincinnati, Ohio, 45242, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
ProMedica Toledo Hospital
Toledo, Ohio, 43606, United States
Ascension St. John Hospital
Tulsa, Oklahoma, 74104, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
OnSite Clinical Solutions, LLC - Rock Hill
Rock Hill, South Carolina, 29732, United States
TriStar Centennial Medical Center
Nashville, Tennessee, 37203, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
St. David's Heart and Vascular dba Austin Heart - Main Office
Austin, Texas, 78705, United States
Methodist Dallas Medical Center
Dallas, Texas, 75203, United States
Houston Methodist Hospital
Houston, Texas, 77030, United States
University of Texas Medical Branch - Galveston
Houston, Texas, 77555, United States
Baylor Scott and White - The Heart Hospital Baylor Plano
Plano, Texas, 75093, United States
Methodist Hospital - San Antonio
San Antonio, Texas, 78229, United States
Houston Methodist Sugar Land Hospital
Sugar Land, Texas, 77479, United States
University of Utah Hospital & Clinics
Salt Lake City, Utah, 84112, United States
St. Boniface Hospital
Winnipeg, Mantioba, R2H 2A6, Canada
Montreal Heart Institute - Institut de Cardiologie de Montreal
Montreal, Quebec, H1T 1C8, Canada
Centre Hospitalier de l Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0C1, Canada
Institut Universitaire de Cardiologie et de Pneumologie De Quebec
Québec, Quebec, GIV 4G5, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 13, 2025
First Posted
June 3, 2025
Study Start
June 27, 2025
Primary Completion (Estimated)
August 31, 2028
Study Completion (Estimated)
September 30, 2030
Last Updated
May 6, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share